Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. (CUE) on June 26, 2020, reporting events occurring on June 24, 2020. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Cambridge, Massachusetts.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on a material definitive agreement regarding lease terms.
Material Changes
On June 24, 2020, the Company entered into a Second Amendment to its License Agreement with MIL 21E, LLC for its facility at 21 Erie Street, Cambridge, MA (approximately 19,833 rentable square feet). Key changes include:
- Term Extension: The lease term was extended to June 14, 2022.
- Rent Increase: The monthly rental rate for the final 14 months of the lease term increased from $297,495 to $375,174.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed beyond the execution of the amended lease agreement.
Investor Verification Checklist
- Verify the total additional rent obligation incurred over the remaining 14-month term due to the rate increase.
- Confirm the Company's current cash position to ensure it can meet the increased monthly lease payments of $375,174.
- Review the full text of Exhibit 10.1 (Second Amendment to License Agreement) for any additional covenants or termination rights.